BioSpace News Archive

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced that management will present company overviews at the following conferences which are being held virtually:

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced positive topline data from its JUNIPER Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical trial of its investigational drug candidate DaxibotulinumtoxinA

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the publication of its FX-322 Phase 1/2 study results in Otology & Neurotology, a leading peer-reviewed journal focused on disorders of the ear.

Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, will report fourth quarter and fiscal year 2020 financial results after the market closes on Thursday, February 25, 2021.

Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Cowen Healthcare Conference on Monday, March 1, 2021 at 11:40 a.m. ET. The video will be simultaneously webcast on www.danaher.com.

Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its full year 2020 financial results after market close on Tuesday, March 9, 2021.

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that its board of directors has amended its shareholder rights plan.

bluebird bio, Inc. announced that members of the management team will participate in the 10th Annual SVB Leerink Global Healthcare Conference, Thursday, February 25, at 12:00 p.m. ET.

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the appointment of Thomas Ebeling, a leading international executive with extensive experience in the healthcare, media and consumer goods industries, as a member of the Supervisory Board with immediate effect.

Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 42 nd Annual Raymond James Institutional Investors Conference. The virtual fireside chat is scheduled to begin at 12:30 p.m. ET on Monday, March 1, 2021.